DURHAM, N.C.--(BUSINESS WIRE)--Argos Therapeutics today announced the presentation of data on the immunosuppressive properties of its soluble CD83 (sCD83) protein at the 2008 American Transplant Congress, held May 31 – June 4 in Toronto, Ontario. The presentation, which will be made on June 3 by Argos’ collaborating scientists at the University of Western Ontario, will review data demonstrating that sCD83-treated dendritic cells from non-human primates are able to induce regulatory T cells in vitro.
